Research advances on risk factors and preventions of renal scar associated with primary vesicoureteral reflux

References:

[1] Kara E,Sakaci T,Ahbap E,et al.Posttransplant urinary tract infection rates and graft outcome in kidney transplantation for end-stage renal disease due to reflux nephropathy versus chronic glomerulonephritis[J].Transplant Proc,2016,48(6):2065-2071.DOI:10.1016/j.transproceed.2016.05.009.
[2] Carpenter MA,Hoberman A,Mattoo TK,et al.The RIVUR trial:profile and baseline clinical associations of children with vesicoureteral reflux[J].Pediatrics,2013,132(1):e34-e45.DOI:10.1542/peds.2012-2301.
[3] Mattoo TK.Vesicoureteral reflux and reflux nephropathy[J].Adv Chronic Kidney Dis,2011,18(5):348-354.DOI:10.1053/j.ackd.2011.07.006.
[4] Hodson CJ,Maling TM,McManamon PJ,et al.The pathogenesis of reflux nephropathy(chronic atrophic pyelonephritis)[J].Br J Radiol,1975,48(Suppl 13):1-26.
[5] Hewitt I,Montini G.Vesicoureteral reflux is it important to find?[J].Pediatr Nephrol,2021,36(4):1011-1017.DOI:10.1007/s00467-020-04573-9.
[6] García Nieto VM,Monge Zamorano M,Antón Hernández L,et al.Reflux nephropathy and scarring nephropathy:so close and yet so different[J].An Pediatr (Engl Ed),2022,97(1):40-47.DOI:10.1016/j.anpede.2021.08.008.
[7] Johnston DL,Qureshi AH,Irvine RW,et al.Contemporary management of vesicoureteral reflux[J].Curr Treat Options Pediatr,2016,2(2):82-93.DOI:10.1007/s40746-016-0045-9.
[8] Shaikh N,Ewing AL,Bhatnagar S,et al.Risk of renal scarring in children with a first urinary tract infection:a systematic review[J].Pediatrics,2010,126(6):1084-1091.DOI:10.1542/peds.2010-0685.
[9] Murugapoopathy V,McCusker C,Gupta IR.The pathogenesis and management of renal scarring in children with vesicoureteric reflux and pyelonephritis[J].Pediatr Nephrol,2020,35(3):349-357.DOI:10.1007/s00467-018-4187-9.
[10] Mattoo TK,Chesney RW,Greenfield SP,et al.Renal scarring in the randomized intervention for children with vesicoureteral reflux (RIVUR) trial[J].Clin J Am Soc Nephrol,2016,11(1):54-61.DOI:10.2215/CJN.05210515.
[11] Peters CA,Skoog SJ,Arant BS Jr,et al.Summary of the AUA guideline on management of primary vesicoureteral reflux in children[J].J Urol,2010,184(3):1134-1144.DOI:10.1016/j.juro.2010.05.065.
[12] Pecile P,Miorin E,Romanello C,et al.Age-related renal parenchymal lesions in children with first febrile urinary tract infections[J].Pediatrics,2009,124(1):23-29.DOI:10.1542/peds.2008-1192.
[13] Mihi B,Good M.Impact of Toll-like receptor 4 signaling in necrotizing enterocolitis:the state of the science[J].Clin Perinatol,2019,46(1):145-157.DOI:10.1016/j.clp.2018.09.007.
[14] Ragnarsdóttir B,Samuelsson M,Gustafsson MCU,et al.Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria[J].J Infect Dis,2007,196(3):475-484.DOI:10.086/518893.
[15] Kollmann TR,Kampmann B,Mazmanian SK,et al.Protecting the newborn and young infant from infectious diseases:lessons from immune ontogeny[J].Immunity,2017,46(3):350-363.DOI:10.1016/j.immuni.2017.03.009.
[16] Zulic E,Hadzic D,Cosickic A,et al.Frequency of urinary tract infection when diagnosing vesico uretheral reflux in children in Tuzla Canton[J].Mater Sociomed,2023,35(1):4-7.DOI:10.5455/msm.2023.35.4-7.
[17] Albracht CD,Hreha TN,Hunstad DA.Sex effects in pyelonephritis[J].Pediatr Nephrol,2021,36(3):507-515.DOI:10.1007/s00467-020-04492-9.
[18] Hreha TN,Collins CA,Daugherty AL,et al.Androgen-Influenced polarization of activin A-producing macrophages accompanies post-pyelonephritic renal scarring[J].Front Immunol,2020,11:1641.DOI:10.3389/fimmu.2020.01641.
[19] Pepe G,Locati M,Della Torre S,et al.The estrogen-macrophage interplay in the homeostasis of the female reproductive tract[J].Hum Reprod Update,2018,24(6):652-672.DOI:10.1093/humupd/dmy026.
[20] Straub RH.The complex role of estrogens in inflammation[J].Endocr Rev,2007,28(5):521-574.DOI:10.1210/er.2007-0001.
[21] Shaikh N,Haralam MA,Kurs-Lasky M,et al.Association of renal scarring with number of febrile urinary tract infections in children[J].JAMA Pediatr,2019,173(10):949-952.DOI:10.1001/jamapediatrics.2019.2504.
[22] O’Brien VP,Hannan TJ,Yu L,et al.A mucosal imprint left by prior Escherichia coli bladder infection sensitizes to recurrent disease[J].Nat Microbiol,2016,2:16196.DOI:10.1038/nmicrobiol.2016.196.
[23] Sürmeli D?ven S,Erdo?an S.Vitamin D deficiency as a risk factor for renal scarring in recurrent urinary tract infections[J].Pediatr Int,2021,63(3):295-299.DOI:10.1111/ped.14397.
[24] Shaikh N,Mattoo TK,Keren R,et al.Early antibiotic treatment for pediatric febrile urinary tract infection and renal scarring[J].JAMA Pediatr,2016,170(9):848-854.DOI:10.1001/jamapediatrics.2016.1181.
[25] Kosmeri C,Kalaitzidis R,Siomou E.An update on renal scarring after urinary tract infection in children:what are the risk factors?[J].J Pediatr Urol,2019,15(6):598-603.DOI:10.1016/j.jpurol.2019.09.010.
[26] Risdon RA.Reflux nephropathy[J].Diagn Histopathol,1981,4(1):61-70.
[27] Muniz G,Kar E,Gumus S,et al.Constipation on abdominal radiograph as potential risk factor for recurrent urinary tract infection development[J].Pediatr Nephrol,2021,36(9):2769-2775.DOI:10.1007/s00467-021-04973-5.
[28] Meena J,Mathew G,Hari P,et al.Prevalence of bladder and bowel dysfunction in toilet-trained children with urinary tract infection and/or primary vesicoureteral reflux:a systematic review and meta-analysis[J].Front Pediatr,2020,8:84.DOI:10.3389/fped.2020.00084.
[29] Schneider KO,Lindemeyer K,Kammer B.Intrarenal reflux,an overlooked entity-retrospective analysis of 1,166 voiding cysturethrographies in children[J].Pediatr Radiol,2019,49(5):617-625.DOI:10.1007/s00247-018-04330-z.
[30] Simi?i? Majce A,Arapovi? A, ?apkun V,et al.The spectrum of parenchymal changes in kidneys affected by intrarenal reflux,diagnosed by contrast-enhanced voiding urosonography and DMSA scan[J].Front Pediatr,2022,10:886112.DOI:10.3389/fped.2022.886112.
[31] Arapovi? A,Punda A,Brdar D,et al.Types of parenchymal changes diagnosed on DMSA scans of kidneys affected by different grades of vesicoureteral reflux[J].Med Sci Monit,2021,27:e929617.DOI:10.12659/MSM.929617.
[32] Everaert K,Van Laecke E,Dekuyper P,et al.Impact of urinary tract infection and detrusor pressure on renal tubular function in patients with vesicoureteral reflux[J].Eur Urol,2001,39(3):337-342.DOI:10.1159/000052464.
[33] Goren MR,Ceyhan E,Ozer C,et al.The impact of reflux pressure on renal scarring in children with sterile vesicoureteral reflux[J].J Pediatr Urol,2023,19(1):130.e1-130.e5.DOI:10.1016/j.jpurol.2022.09.016.
[34] Watson AR.Management of urinary tract infection in children[J].BMJ,2007,335(7616):356-357.DOI:10.1136/bmj.39309.423542.80.
[35] Tullus K.What do the latest guidelines tell us about UTIs in children under 2 years of age[J].Pediatr Nephrol,2012,27(4):509-511.DOI:10.1007/s00467-011-2077-5.
[36] Subcommittee on Urinary Tract Infection,Steering Committee on Quality Improvement and Management,Roberts KB.Urinary tract infection:clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months[J].Pediatrics,2011,128(3):595-610.DOI:10.1542/peds.2011-1330.
[37] Brandstr?m P,Nevéus T,Sixt R,et al.The Swedish reflux trial in children:IV.Renal damage[J].J Urol,2010,184(1):292-297.DOI:10.1016/j.juro.2010.01.060.
[38] Damm T,Mathews R.The RiVUR study outcomes and implications on the management of vesicoureteral reflux[J].Arch Nephrol Ren Stud,2022,2(1):1-5.
[39] Hari P,Bagga A.Antimicrobial prophylaxis for children with vesicoureteral reflux[J].N Engl J Med,2014,370(11):1071-1072.DOI:10.1056/NEJMc1408559.
[40] Mathews R,Mattoo TK.The role of antimicrobial prophylaxis in the management of children with vesicoureteral reflux-the RIVUR study outcomes[J].Adv Chronic Kidney Dis,2015,22(4):325-330.DOI:10.1053/j.ackd.2015.04.002.
[41] Wang HH,Kurtz M,Logvinenko T,et al.Why does prevention of recurrent urinary tract infection not result in less renal scarring? A deeper dive into the RIVUR trial[J].J Urol,2019,202(2):400-405.DOI:10.1097/JU.0000000000000292.
[42] Hoberman A,Greenfield SP,Mattoo TK,et al.Antimicrobial prophylaxis for children with vesicoureteral reflux[J].N Engl J Med,2014,370(25):2367-2376.DOI:10.1056/NEJMoa1401811.
[43] Shaikh N,Rajakumar V,Peterson CG,et al.Cost-utility of antimicrobial prophylaxis for treatment of children with vesicoureteral reflux[J].Front Pediatr,2019,7:530.DOI:10.3389/fped.2019.00530.
[44] Bertsimas D,Li M,Estrada C,et al.Selecting children with vesicoureteral reflux who are most likely to benefit from antibiotic prophylaxis:application of machine learning to RIVUR[J].J Urol,2021,205(4):1170-1179.DOI:10.1097/JU.0000000000001445.
[45] Wang ZT,Wehbi E,Alam Y,et al.A reanalysis of the RIVUR trial using a risk classification system[J].J Urol,2018,199(6):1608-1614.DOI:10.1016/j.juro.2017.11.080.
[46] Mattoo TK,Shaikh N,Nelson CP.Contemporary management of urinary tract infection in children[J].Pediatrics,2021,147(2):e2020012138.DOI:10.1542/peds.2020-012138.
[47] 中华医学会小儿外科学分会泌尿外科学组.儿童原发性膀胱输尿管反流的专家共识[J].临床小儿外科杂志,2019,18(10):811-816.DOI:10.3969/j.issn.1671-6353.2019.10.002.Group of Urology,Branch of Pediatric Surgery,Chinese Medical Association:Expert Consensus on Managing Primary Vesicoureteral Reflux in Children[J].J Clin Ped Sur,2019,18(10):811-816.DOI:10.3969/j.issn.1671-6353.2019.10.002.
[48] Su DQ,Shen Q,Zhai YH,et al.Risk factors for breakthrough urinary tract infection in children with vesicoureteral reflux receiving continuous antibiotic prophylaxis[J].Transl Pediatr,2022,11(1):1-9.DOI:10.21037/tp-21-398.